Nordic Nanovector ASA (OSE: NANO), a company focusing on the development
and commercialization of novel targeted therapeutics in haematology and
oncology, announces that its CFO Tone Kvåle will present at the
Swiss-Scandinavian Bio-Business seminar in Zurich, Switzerland on 10
February 2016. The slides of the presentation given will be available on
the Nordic Nanovector website in the section: Investor Relations/Reports
and Presentations/Presentations/2016. ###
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company’s lead clinical-stage product opportunity is
Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates
(ARC) designed to improve upon and complement current options for the
treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with
substantial unmet medical need and orphan drug opportunities,
representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1)
conjugated to a low intensity radionuclide (lutetium- 177). It has shown
promising efficacy and a favourable safety profile in an ongoing Phase
1/2 study in a difficult-to-treat NHL patient population. The Company is
aiming at developing Betalutin® for the treatment of major types of NHL
with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets,
while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its ARC pipeline to
treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160205005355/en/
Copyright Business Wire 2016